Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis
Overview
Authors
Affiliations
Coronavirus disease 2019 (COVID-19) is a global health crisis caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and there is a critical need to produce large quantities of high-quality SARS-CoV-2 Spike (S) protein for use in both clinical and basic science settings. To address this need, we have evaluated the expression and purification of two previously reported S protein constructs in Expi293F and ExpiCHO-S cells, two different cell lines selected for increased protein expression. We show that ExpiCHO-S cells produce enhanced yields of both SARS-CoV-2 S proteins. Biochemical, biophysical, and structural (cryo-EM) characterizations of the SARS-CoV-2 S proteins produced in both cell lines demonstrate that the reported purification strategy yields high-quality S protein (nonaggregated, uniform material with appropriate biochemical and biophysical properties), and analysis of 20 deposited S protein cryo-EM structures reveals conformation plasticity in the region composed of amino acids 614-642 and 828-854. Importantly, we show that multiple preparations of these two recombinant S proteins from either cell line exhibit identical behavior in two different serology assays. We also evaluate the specificity of S protein-mediated host cell binding by examining interactions with proposed binding partners in the human secretome and report no novel binding partners and notably fail to validate the Spike:CD147 interaction. In addition, the antigenicity of these proteins is demonstrated by standard ELISAs and in a flexible protein microarray format. Collectively, we establish an array of metrics for ensuring the production of high-quality S protein to support clinical, biological, biochemical, structural, and mechanistic studies to combat the global pandemic caused by SARS-CoV-2.
Quality by design for transient RBD-Fc fusion protein production in Chinese hamster ovary cells.
Jivapetthai A, Arunmanee W, Pornputtapong N Biotechnol Rep (Amst). 2025; 45:e00882.
PMID: 40034964 PMC: 11872631. DOI: 10.1016/j.btre.2025.e00882.
Laghlali G, Wiest M, Karadag D, Warang P, OKonek J, Chang L Mol Ther. 2024; 32(12):4448-4466.
PMID: 39489918 PMC: 11638833. DOI: 10.1016/j.ymthe.2024.10.016.
In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins.
Nafian F, Soleymani G, Pourmanouchehri Z, Kiyanjam M, Nafian S, Mohammadi S Adv Virol. 2024; 2024:3418062.
PMID: 39380944 PMC: 11459942. DOI: 10.1155/2024/3418062.
Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells.
Michaels T, Essop M, Joseph D Viruses. 2024; 16(8).
PMID: 39205219 PMC: 11358987. DOI: 10.3390/v16081243.
Yevsieieva L, Lohachova K, Kyrychenko A, Kovalenko S, Ivanov V, Kalugin O RSC Adv. 2023; 13(50):35500-35524.
PMID: 38077980 PMC: 10698513. DOI: 10.1039/d3ra06479d.